Hui-Gene collected $14.2m from investors including WuXi AppTec and the Mayo Clinic-backed Huimei Healthcare Management to progress its gene therapy pipeline toward clinical testing and production.
China-based gene therapy developer Hui-Gene Therapeutics raised more than RMB100m ($14.2m) yesterday in a series A round that included pharmaceutical firm WuXi AppTec.
Venture capital firm CD Capital led the round, which included Huimei Healthcare Management – a VC partnership between clinical research firm Mayo Clinic and hedge fund manager Hillhouse Capital – and which was filled out by VC firms Sherpa Capital and Alwin Capital.
Founded in 2018, Hui-Gene is working on drugs for single-gene disorders for which the…
